Table 3 Immune-related markers and mechanism analysis of PIWIL4 and SUPT5H
Gene | Types | Target | Spearman correlation analysis | p value | Survival | p value |
|---|---|---|---|---|---|---|
PIWIL4 | Chemokin | CCL24 | − 0.434 | p < 0.001 |  | p = 0.00626 |
| Â | receptor | CCR9 | 0.344 | 0.0408 | Â | Â |
SUPT5H | Chemokin | CXCL5 | − 0.419 | 0.0116 |  | p = 0.0234 |
| Â | Â | CXCL12 | 0.405 | 0.0148 | Â | Â |
|  |  | CXCL16 | − 0.359 | 0.0321 |  |  |
| Â | Immunoinhibitor | IL10RB | 0.44 | 0.00775 | Â | Â |
| Â | Â | PVRL2 | 0.52 | 0.00133 | Â | Â |
| Â | Immunostimulator | CD276 | 0.357 | 0.0331 | Â | Â |
| Â | Â | CXCL12 | 0.405 | 0.0148 | Â | Â |
|  |  | ENTPD1 | − 0.364 | 0.0297 |  |  |
|  |  | TMEM173 | − 0.334 | 0.0473 |  |  |
|  |  | TNFSF4 | − 0.337 | 0.0447 |  |  |
|  |  | TNFSF13 | − 0.382 | 0.0222 |  |  |
|  | CHOL_MHC | HLA-DOB | − 0.367 | 0.0282 |  |  |
|  | CHOL_TIL_TEM | Tem CD4 cells | − 0.349 | 0.0376 |  |  |
| Â | CHOL_TIL_Th2 | Th2 cells | Â | Â | Â | Â |
|  | CHOL_TIL_Th17 | Th17 cells | − 0.421 | 0.0112 |  |  |
PIWIL4 | Â | Â | Â | Â | Â |
|---|---|---|---|---|---|
Cancer type | Drug | Group | Res vs N-Res | Log2(FC) | p value |
Melanoma | Anti-PD-1(pembrolizumab and nivolumab) | All | 14 vs 12 | − 0.524 | 0.0385 |